The Research Working Group seeks to bridge the missing mile between basic research and the commercialization of products. Having an equal partnership between the Virtual Physiological Human Institute (VPH) and industries engaged in predictive medicine provides a unique opportunity to explore areas of mutual cooperation and benefit.

The key goals of this group are:

  • Promotion of in silico medicine in Horizon 2020;
  • Working towards the creation of a Public Private Partnership (PPP) on in silico medicine;
  • Creating links between the VPH Membership and Avicenna Industry Members


Priorities in 2018

→ Further develop a comprehensive position for Avicenna on what is needed in EU research;
→ Launch of the new Avicenna Alliance internship scheme;
→ A core focus of the VPH membership is on the FET Flagship on ageing and on shaping this Flagship programme;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Working group leader:

  • Liesbet Geris
  • Executive Director, VPH Institute
  • Professor, University of Liège & KU Leuven (Belgium)

Avicenna Alliance news

Avicenna present at the European Research & Innovation Days

The European Research and Innovation days was a three-day event in Brussels, during which researchers, academics, businesses,...

find out more ›

SAVE THE DATE! Ansys-FDA-Avicenna event in Washington on 11 October 2019

Innovation through healthcare simulationFor those of you who will be in Washington mid-October, ANSYS, in cooperation with the...

find out more ›

Avicenna answers online consultation to shape Horizon Europe

On 23 July the Avicenna Alliance has submitted its opinion to on the strategic priorities of Horizon Europe, the EU’s next framework...

find out more ›

Prestigious FDA award allocated to group that developed the V&V 40 standard

The Avicenna Alliance is proud to announce that some of its working group members have received the FDA Crosscutting Group...

find out more ›

Show all activites

Sign up for our monthly newsletter!


Sign up